# OnCo record immix-biopharma (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/immix-biopharma/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "immix-biopharma" ;
  schema:name "Immix Biopharma"@en ;
  schema:alternateName "Immix Biopharma, Inc."@en, "Nexcella"@en, "NASDAQ:IMMX"@en ;
  schema:description "Immix Biopharma is a Los Angeles cell-therapy company whose BCMA CAR-T NXC-201 is the first CAR-T to show deep responses in AL amyloidosis, the disease in which misfolded antibody fragments damage the heart and kidneys."@en ;
  schema:url <https://onco.cc/companies/immix-biopharma/>, <https://www.immixbio.com/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://www.immixbio.com/> ;
  onco:tag "drug-maker" ;
  schema:addressCountry "US" ;
  onco:drugs <https://onco.cc/drugs/nxc-201-car-t/> .